An association between cutaneous melanoma and non-Hodgkin's lymphoma: Pooled analysis of published data with a review

Annals of Oncology

Volumn 16, Issue 3, 2005, Pages 460-465

  Lens, Marko B ^a,b   Newton Bishop, J A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Association; Cutanous melanoma; Non Hodgkin's lymphoma

Indexed keywords

ADULT; AGED; ARTICLE; CALCULATION; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SKIN TUMOR; STANDARDIZATION; STATISTICAL SIGNIFICANCE;

EID: 16244388276     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi080     Document Type: Article

References (39)

1. Devesa SS, Fears T. Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 1992; 52 (Suppl 19): 5432s-5440s.
2. Marks R. Epidemiology of melanoma. Clin Exp Dermatol 2000; 25: 459-463.
3. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001; 63: 8-18.
4. Cahill RA, McGreal G, Neary P, Redmond HP. Synchronous high-risk melanoma and lymphoid neoplasia. Mel Res 2001; 11: 517-522.
5. Riou JP, Ariyan S, Brandow KR, Fielding LP. The association between melanoma, lymphoma, and other primary neoplasms. Arch Surg 1995; 130: 1056-1061.
6. Begg CB, Zhang ZF, Sun M et al. Methodology for evaluating the incidence of second primary cancers with application to smoking-related cancers from the Surveillance, Epidemiology, and End Results (SEER) program. Am J Epidemiol 1995; 142: 653-665.
7. McKenna DB, Stockton D, Brewster DH, Doherty VR. Evidence for an association between cutaneous melanoma and lymphoid malignancy: a population-based retrospective cohort study in Scotland. Br J Cancer 2003; 88: 74-78.
8. Goggins WB, Finkelstein DM, Tsao H. Evidence for an association between cutaneous melanoma and non-Hodgkin's lymphoma. Cancer 2001; 91: 874-880.
9. Dong C, Hemminki K. Second primary neoplasms among 53159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms. Br J Cancer 2001; 85: 997-1005.
10. Brennan P, Coates M, Armstrong B et al. Second primary neoplasms following non-Hodkin's lymphoma in New South Wales, Australia. Br J Cancer 2000; 82: 1344-1347.
11. Levi F, Randimbison L, Te VC, La Vecchia C. Non-Hodgkin's lymphoma, chronic lymphocytic leukaemias and skin cancers. Br J Cancer 1996; 74: 1847-1850.
12. Adami J, Frisch M, Yuen J et al. Evidence for an association between non-Hodgkin's lymphoma and skin cancer. BMJ 1995; 310: 1491-1495.
13. Hall P, Rosendahl I, Mattsson A, Einhorn S. Non-Hodgkin's lymphoma and skin malignancies-shared etiology? Int J Cancer 1995; 62: 519-522.
14. Greene MH, Wilson J. Second cancer following lymphatic and hematopoietic cancers in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985; 68: 191-217.
15. Tucker MA, Boice JD Jr, Hoffman DA. Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985; 68: 161-189.
16. Osterlind A, Olsen JH, Lynge E, Ewertz M. Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Denmark, 1943-80. Natl Cancer Inst Monogr 1985; 68: 361-388.
17. Storm HH, Prener A. Second cancer following lymphatic and hematopoietic cancers in Denmark, 1943-80. Natl Cancer Inst Monogr 1985; 68: 389-409.
18. Teppo L, Pukkala E, Saxen E. Multiple cancer-an epidemiologic exercise in Finland. J Natl Cancer Inst 1985; 75: 207-217.
19. Bishop DT, Demenais F, Goldstein AM et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002; 94: 894-903.
20. van der Velden PA, Sandkuijl LA, Bergman W et al. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 2001; 69: 774-779.
21. Maldonado JL, Fridlyand J, Patel H et al. Determinants of BRAF mutations in primary melanoma. J Natl Cancer Inst 2003; 95: 1878-1890.
22. Cohen Y, Rosenbaum E, Begum S et al. Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin Cancer Res 2004; 10: 3444-3447.
23. McKenna DB, Doherty VR, McLaren KM, Hunter JA. Malignant melanoma and lymphoproliferative malignancy: is there a shared aetiology? Br J Dermatol 2000; 143: 171-173.
24. McMichael AJ, Giles GG. Have increases in solar ultraviolet exposure contributed to the rise in incidence of non-Hodgkin's lymphoma? Br J Cancer 1996; 73: 945-950.
25. Streilein JW, Taylor JR, Vincek V et al. Relationship between ultraviolet radiation-induced immunosuppression and carcinogenesis. J Invest Dermatol 1994; 103 (Suppl 5): 107S-111S.
26. Saijo S, Bucana CD, Ramirez KM et al. Deficient antigen presentation and Ts induction are separate effects of ultraviolet irradiation. Cell Immunol 1995; 164: 189-202.
27. Bentham G. Association between incidence of non-Hodgkin's lymphoma and solar ultraviolet radiation in England and Wales. BMJ 1996; 312: 1128-1131.
28. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000; 92: 1240-1251.
29. Newton R. Non-Hodgkin's lymphoma and skin cancer. American data refute ultraviolet hypothesis. BMJ 1995; 311: 750-751.
30. Boldeman C, Brandt L, Berg L et al. Risk of non-Hodgkin's lymphoma and skin malignancies in patients diagnosed with cancer. Eur J Cancer Prev 2004; 13: 281-285.
31. Highes AM, Armstrong BK, Vajdic CM et al. Sun exposure may protect against non-Hodgkin lymphoma: a case-control study. Int J Cancer 2004; 112: 865-871.
32. Travis LB, Curtis RE, Glimelius B et al. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 1993; 85: 1932-1937.
33. Werkmeister J, Phillips G, McCarthy W, Hersey P. Suppressor cell activity in melanoma patients. II. Concanavalin A-induced suppressor cells in relation to tumor growth and suppressor T-cell subsets. Int J Cancer 1981; 28: 11-15.
34. Vanhaelen CP, Fisher RI. Increased sensitivity of T cells to regulation by normal suppressor cells persists in long-term survivors with Hodgkin's disease. Am J Med 1982; 72: 385-390.
35. Cannon-Albright LA, Thomas A, Goldgar DE et al. Familiality of cancer in Utah. Cancer Res 1994; 54: 2378-2385.
36. Chatterjee N, Hartge P, Cerhan JR et al. Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers. Cancer Epidemiol Biomarkers Prev 2004; 13: 1415-1421.
37. Randerson-Moor JA, Harland M, Williams S et al. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 2001; 10: 55-62.
38. Hewitt C, Lee Wu C, Evans G et al. Germline mutation of ARF in a melanoma kindred. Hum Mol Genet 2002; 11: 1273-1279.
39. Gillanders E, Juo SH, Holland EA et al. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet 2003; 73: 301-313.